Overview

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2021-10-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects of repeat dosing of JNJ-56021927 on the pharmacokinetics for single-dose multiple cytochrome P450 (CYP450) enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2C8) and transporter (P-gp and BRCP) substrates in participants with castration-resistant prostate cancer (CRPC).

Phase:

Phase 1

Details

Lead Sponsor:

Aragon Pharmaceuticals, Inc.

Treatments:

Pioglitazone
Rosuvastatin Calcium